We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Vaccines Target Ticks, Not Disease

By Biotechdaily staff writers
Posted on 23 May 2002
Researchers are exploring the possibility of preventing tick-borne diseases by developing vaccines against the tick vector rather than against the pathogenic microorganisms that actually cause the disease. More...
Ticks harbor the causative agents for several serious diseases of animals and humans, including Lyme disease, Rocky Mountain spotted fever, Ehrlichiosis and relapsing fever. The research was described in a presentation given during the spring meeting of the Society for General Microbiology held at the University of Warwick (UK).

"A new solution to controlling tick-borne diseases is to develop vaccines against the ticks and not the microbes that cause the diseases. We have experimental vaccines containing molecules found on the tick's gut wall, which prevent the digestion of the blood meal and stop females from laying their eggs,” says Dr. Olivier Sparagano of Newcastle University (England).

So far it has been shown that the prototype vaccines reduce the fertility of female ticks and lessen the chances of survival of their larvae. Lowering the number of ticks will reduce the risk of animals and humans coming in contact with the disease-bearing arthropods. Dr. Sparagano warned that changes in climate are making Great Britain more suitable for ticks, and that incidence of tick-borne diseases are on the increase. He stressed that the import of ticks from southern Europe, Africa, and Asia should be prevented as far as possible while new methods for controlling the spread of tick-borne diseases are being developed.




Related Links:
Univ. of Newcastle upon Tyne

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.